

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 JANUARY 2019
ERRATA

(1) This Erratum removes the following item codes and indications for cetuximab from the 1 January 2019 Schedule of Pharmaceutical Benefits as detailed below.

Chemotherapy items for Public Hospital use

▪ **CETUXIMAB**

Note Special Pricing Arrangements apply.

Note No increase in the maximum number of repeats may be authorised.

Authority required (STREAMLINED)

8286

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Continuing treatment

Clinical criteria:

- Patient must have previously received a PBS-subsidised loading dose of this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with platinum-based chemotherapy for up to 6 cycles, after which it must be used as monotherapy.

Injection

11587W

Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
550 mg	22	..	*1833.78	40.30	Erbix [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbix [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ CETUXIMAB

Note Special Pricing Arrangements apply.

Note No increase in the maximum number of repeats may be authorised.

Authority required (STREAMLINED)

8305

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Initial treatment - loading dose

Clinical criteria:

- The condition must be previously untreated, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The treatment must be in combination with platinum-based chemotherapy.

Injection

11609B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	880 mg	*2708.46	40.30	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

Chemotherapy items for Private Hospital use

▪ CETUXIMAB

Note Special Pricing Arrangements apply.

Note No increase in the maximum number of repeats may be authorised.

Authority required (STREAMLINED)

8286

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Continuing treatment

Clinical criteria:

- Patient must have previously received a PBS-subsidised loading dose of this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with platinum-based chemotherapy for up to 6 cycles, after which it must be used as monotherapy.

Injection

11601N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	22	..	*1897.49	40.30	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

■ CETUXIMAB

Note Special Pricing Arrangements apply.

Note No increase in the maximum number of repeats may be authorised.

Authority required (STREAMLINED)**8305**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Initial treatment - loading dose

Clinical criteria:

- The condition must be previously untreated, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The treatment must be in combination with platinum-based chemotherapy.

Injection

11610C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	880 mg	*2784.41	40.30	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)